2023 Fellowships

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Term: Two Years

Amount: $200,000

This cancer immunotherapy translational fellowship aims to support an MD, PhD, or combined MD/PhD individual with a vested interest in furthering the research and translation of cancer immunotherapy.

Learn More

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Term: One Year

Amount: $100,000

This clinical fellowship supports an MD or combined MD/PhD degree with a vested interest in furthering the research and translation of immunotherapeutic approaches for the treatment of patients with lung cancer.

Learn More

SITC-Genentech Women in Cancer Immunotherapy Fellowship

Term: One Year

Amount: $100,000

This fellowship supports the development of a female immunotherapy expert who has an MD, a PhD or combined MD/PhD with a vested interest in furthering research in cancer immunotherapy. Priority will be given to female applicants who self-identify ethnic minority status according to the NIH’s guidance on underrepresented populations. U.S.-based applicants only.

Learn More

SITC-Merck Cancer Immunotherapy Clinical Fellowship

Term: One Year

Amount: $100,000

This clinical fellowship supports an MD or combined MD/PhD with a vested interest in furthering the research and translation of cancer immunotherapy.

Learn More

SITC Diversity, Equity and Inclusion Fellowship

Term: One Year

Amount: $100,000

This fellowship supports clinical or translational research in cancer immunotherapy and will be awarded to an MD, PhD or combined MD/PhD who self-identifies ethnic minority status according to the NIH’s guidance on underrepresented populations.

Learn More

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship

Term: One Year

Amount: $40,000

This fellowship provides support to an individual with an MD (or equivalent) or combined MD/PhD degree with a vested interest in furthering the research and translation of adverse events in cancer immunotherapy.

Learn More